drugset / Trial / NCT05789589

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589

NaSequentialOpen-labelTreatment

Summary

To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).

Timeline

Start
2023-11-17
Primary completion
2027-03-16
Completion
2027-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azeliragon Small molecule 5 mg Oral
Subject Azeliragon Small molecule 10 mg Oral
Subject Azeliragon Small molecule 20 mg Oral
Background Dexamethasone Small molecule 2 mg Oral
Background Dexamethasone Small molecule 4 mg Oral
Background Methylprednisolone Other / unclassified 40 mg
Background Methylprednisolone Other / unclassified 80 mg